PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34595177-4 2021 We evaluated HIF1alpha expression immunohistochemically from biopsies of 108 BC patients receiving paclitaxel-cisplatin NAT. Cisplatin 110-119 hypoxia inducible factor 1 subunit alpha Homo sapiens 13-22 34385105-0 2021 Panax notoginseng saponins reduces the cisplatin-induced acute renal injury by increasing HIF-1alpha/BNIP3 to inhibit mitochondrial apoptosis pathway. Cisplatin 39-48 hypoxia inducible factor 1 subunit alpha Homo sapiens 90-100 34385105-2 2021 As a new Chinese herbal preparation, Panax notoginseng saponins (PNS) has been found to mitigate CDDP-induced CAKI through elevating the expression of HIF-1alpha in the rat model, according to the data from our previous works. Cisplatin 97-101 hypoxia inducible factor 1 subunit alpha Homo sapiens 151-161 34385105-8 2021 Our results showed that treatment of PNS rescued the cell viability of CDDP-injured HK-2 or HIF-1alpha-knockdown HK-2 cells, and increased the expression levels of ATP and MMP in HK-2 or HIF-1alpha-knockdown HK-2 cells which were reduced by CDDP. Cisplatin 241-245 hypoxia inducible factor 1 subunit alpha Homo sapiens 92-102 34385105-8 2021 Our results showed that treatment of PNS rescued the cell viability of CDDP-injured HK-2 or HIF-1alpha-knockdown HK-2 cells, and increased the expression levels of ATP and MMP in HK-2 or HIF-1alpha-knockdown HK-2 cells which were reduced by CDDP. Cisplatin 241-245 hypoxia inducible factor 1 subunit alpha Homo sapiens 187-197 34899911-11 2021 Finally, PC4 destabilized HIF-1alpha upon cisplatin treatment. Cisplatin 42-51 hypoxia inducible factor 1 subunit alpha Homo sapiens 26-36 34415232-0 2021 MicroRNA-624-mediated ARRDC3/YAP/HIF1alpha axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel. Cisplatin 111-120 hypoxia inducible factor 1 subunit alpha Homo sapiens 33-42 34460078-0 2021 Hypoxia-induced ROS promotes mitochondrial fission and cisplatin chemosensitivity via HIF-1alpha/Mff regulation in head and neck squamous cell carcinoma. Cisplatin 55-64 hypoxia inducible factor 1 subunit alpha Homo sapiens 86-96 34460078-13 2021 CONCLUSIONS: Our findings indicate that hypoxia-induced release of ROS can promote mitochondrial fission and CDDP chemosensitivity via HIF1alpha/Mff regulation in HNSCC cells, indicating that Mff may serve as a biomarker to predict neoadjuvant chemosensitivity in HNSCC patients and as a target for overcoming chemoresistance. Cisplatin 109-113 hypoxia inducible factor 1 subunit alpha Homo sapiens 135-144 34265288-4 2021 Mechanistically, cisplatin-induced HIF1alpha signaling activation directly drive the transcription of LIF, which promotes the resistance of gastric tumors to chemo drug. Cisplatin 17-26 hypoxia inducible factor 1 subunit alpha Homo sapiens 35-44 35411640-9 2022 It is the first study to demonstrate that FIR effectively attenuates cisplatin-induced vascular damage and impaired angiogenesis through activation of HIF-1alpha-dependent processes via regulation of PLZF, PI3K/Akt. Cisplatin 69-78 hypoxia inducible factor 1 subunit alpha Homo sapiens 151-161 34399762-7 2021 In terms of anti-tumor mechanism, CTP/CDDP reduced CDDP efflux and inhibited epithelial-mesenchymal transition (EMT) process of tumor by down-regulating hypoxia-inducible factor-1alpha (HIF-1alpha), glutathione (GSH), multidrug resistance-associated protein 2 (MRP2) and matrix metalloproteinase 9 (MMP9) expression, thus reversing drug resistance and metastasis of hypoxic tumor cells. Cisplatin 38-42 hypoxia inducible factor 1 subunit alpha Homo sapiens 153-184 34399762-7 2021 In terms of anti-tumor mechanism, CTP/CDDP reduced CDDP efflux and inhibited epithelial-mesenchymal transition (EMT) process of tumor by down-regulating hypoxia-inducible factor-1alpha (HIF-1alpha), glutathione (GSH), multidrug resistance-associated protein 2 (MRP2) and matrix metalloproteinase 9 (MMP9) expression, thus reversing drug resistance and metastasis of hypoxic tumor cells. Cisplatin 38-42 hypoxia inducible factor 1 subunit alpha Homo sapiens 186-196 35411640-0 2022 Far-infrared radiation alleviates cisplatin-induced vascular damage and impaired circulation via activation of HIF-1alpha. Cisplatin 34-43 hypoxia inducible factor 1 subunit alpha Homo sapiens 111-121 32905663-9 2021 Strikingly, low HIF-1alpha level was correlated with improved responsiveness to cisplatin treatment in ovarian cancer patients. Cisplatin 80-89 hypoxia inducible factor 1 subunit alpha Homo sapiens 16-26 35411640-5 2022 Moreover, FIR markedly increased the levels of phosphorylation of PI3K and Akt, and VEGF secretion, as well as the expression and the activity of hypoxia-inducible factor 1alpha (HIF-1alpha) in cisplatin-treated HUVECs via a PLZF dependent manner. Cisplatin 194-203 hypoxia inducible factor 1 subunit alpha Homo sapiens 146-177 35411640-5 2022 Moreover, FIR markedly increased the levels of phosphorylation of PI3K and Akt, and VEGF secretion, as well as the expression and the activity of hypoxia-inducible factor 1alpha (HIF-1alpha) in cisplatin-treated HUVECs via a PLZF dependent manner. Cisplatin 194-203 hypoxia inducible factor 1 subunit alpha Homo sapiens 179-189 35411640-7 2022 We also confirmed that HIF-1alpha, PI3K, and PLZF contribute to the inhibitory effect of FIR on cisplatin-induced apoptosis in HUVECs. Cisplatin 96-105 hypoxia inducible factor 1 subunit alpha Homo sapiens 23-33 33969609-6 2021 Additionally, the non-lethal doses of etoposide and cisplatin can induce SCLC cell stemness in a concentration-dependent manner and reduce the lysosome iron concentration dependent on Ferritin expression, which is positively regulated by HIF-1alpha/beta. Cisplatin 52-61 hypoxia inducible factor 1 subunit alpha Homo sapiens 238-253 33345849-9 2021 The In vivo studies confirmed the effect of IL-6 in increasing the chemoresistance of OvCa cells against cisplatin through the IL-6/STAT3/HIF-1alpha loop in the animal models. Cisplatin 105-114 hypoxia inducible factor 1 subunit alpha Homo sapiens 138-148 35070983-13 2021 The KEGG pathway analysis revealed that quercetin and cisplatin may affect cervical cancer through platinum drug resistance and the p53 and HIF-1 pathways. Cisplatin 54-63 hypoxia inducible factor 1 subunit alpha Homo sapiens 140-145 34046349-7 2021 Further investigations showed that miRNA-21 combined with cisplatin caused excessive inactivation of the pI3K/AKT/mTOR/HIF-1alpha signaling pathway in cisplatin-resistant A549/DDP cells. Cisplatin 58-67 hypoxia inducible factor 1 subunit alpha Homo sapiens 119-129 34046349-7 2021 Further investigations showed that miRNA-21 combined with cisplatin caused excessive inactivation of the pI3K/AKT/mTOR/HIF-1alpha signaling pathway in cisplatin-resistant A549/DDP cells. Cisplatin 151-160 hypoxia inducible factor 1 subunit alpha Homo sapiens 119-129 33290263-5 2020 As a result, Nrf2-dependent transcription counteracts HIF-1alpha degradation under mild hypoxia condition, leading to preferential cisplatin-resistance in HepG2/DDP cells. Cisplatin 131-140 hypoxia inducible factor 1 subunit alpha Homo sapiens 54-64 33413524-0 2021 Correction to: microRNA-216b enhances cisplatin-induced apoptosis in osteosarcoma MG63 and SaOS-2 cells by binding to JMJD2C and regulating the HIF1alpha/HES1 signaling axis. Cisplatin 38-47 hypoxia inducible factor 1 subunit alpha Homo sapiens 144-153 33290263-0 2020 Enhancer-bound Nrf2 licenses HIF-1alpha transcription under hypoxia to promote cisplatin resistance in hepatocellular carcinoma cells. Cisplatin 79-88 hypoxia inducible factor 1 subunit alpha Homo sapiens 29-39 32978517-0 2020 Oroxylin A reverses hypoxia-induced cisplatin resistance through inhibiting HIF-1alpha mediated XPC transcription. Cisplatin 36-45 hypoxia inducible factor 1 subunit alpha Homo sapiens 76-86 32978517-1 2020 Hypoxia is a key concern during the treatment of non-small cell lung cancer (NSCLC), and hypoxia-inducible factor 1 alpha (HIF-1alpha) has been associated with increased tumor resistance to therapeutic modalities such as cisplatin. Cisplatin 221-230 hypoxia inducible factor 1 subunit alpha Homo sapiens 89-121 32978517-1 2020 Hypoxia is a key concern during the treatment of non-small cell lung cancer (NSCLC), and hypoxia-inducible factor 1 alpha (HIF-1alpha) has been associated with increased tumor resistance to therapeutic modalities such as cisplatin. Cisplatin 221-230 hypoxia inducible factor 1 subunit alpha Homo sapiens 123-133 32978517-5 2020 Further data suggested that Oroxylin A significantly reversed the hypoxia-induced cisplatin resistance through directly binding to HIF-1alpha bHLH-PAS domain and blocking its binding to HRE3 transcription factor binding sites on XPC promoter which is important to hypoxia-induced XPC transcription. Cisplatin 82-91 hypoxia inducible factor 1 subunit alpha Homo sapiens 131-141 33239133-0 2020 Aloperine can reverse the cisplatin resistance of colorectal cancer cells via suppressing the HIF-1alpha/ERK signaling pathway. Cisplatin 26-35 hypoxia inducible factor 1 subunit alpha Homo sapiens 94-104 32972441-15 2020 CONCLUSION: Overall, miR-216b enhanced the sensitivity of OS cells to cisplatin via downregulation of the JMJD2C/HIF1alpha/HES1 signaling axis, highlighting the capacity of miR-216b as an adjunct to cisplatin chemotherapy in the treatment of OS. Cisplatin 70-79 hypoxia inducible factor 1 subunit alpha Homo sapiens 113-122 32328193-0 2020 Self-enforcing HMGB1/NF-kappaB/HIF-1alpha Feedback Loop Promotes Cisplatin Resistance in Hepatocellular Carcinoma Cells. Cisplatin 65-74 hypoxia inducible factor 1 subunit alpha Homo sapiens 31-41 32522234-0 2020 HIF-1alpha-dependent miR-424 induction confers cisplatin resistance on bladder cancer cells through down-regulation of pro-apoptotic UNC5B and SIRT4. Cisplatin 47-56 hypoxia inducible factor 1 subunit alpha Homo sapiens 0-10 32522234-9 2020 RESULTS: In this study, we have found for the first time that cisplatin (CDDP) induces the expression of miR-424 in a HIF-1alpha-dependent manner under normoxia, and miR-424 plays a vital role in the regulation of CDDP resistance of bladder cancer cells in vitro. Cisplatin 62-71 hypoxia inducible factor 1 subunit alpha Homo sapiens 118-128 32522234-9 2020 RESULTS: In this study, we have found for the first time that cisplatin (CDDP) induces the expression of miR-424 in a HIF-1alpha-dependent manner under normoxia, and miR-424 plays a vital role in the regulation of CDDP resistance of bladder cancer cells in vitro. Cisplatin 73-77 hypoxia inducible factor 1 subunit alpha Homo sapiens 118-128 32522234-9 2020 RESULTS: In this study, we have found for the first time that cisplatin (CDDP) induces the expression of miR-424 in a HIF-1alpha-dependent manner under normoxia, and miR-424 plays a vital role in the regulation of CDDP resistance of bladder cancer cells in vitro. Cisplatin 214-218 hypoxia inducible factor 1 subunit alpha Homo sapiens 118-128 32432742-0 2020 Autophagy related 4B, upregulated by HIF-1alpha, attenuates the sensitivity to cisplatin in nasopharyngeal carcinoma cells. Cisplatin 79-88 hypoxia inducible factor 1 subunit alpha Homo sapiens 37-47 32432742-8 2020 RESULTS: Our study reveals that HIF-1alpha increased ATG4B expression in NPC cells, and in turn upregulated the cisplatin (DDP)-induced protective autophagy, resulting in enhanced killing effect of DDP to NPC cells. Cisplatin 112-121 hypoxia inducible factor 1 subunit alpha Homo sapiens 32-42 32432742-8 2020 RESULTS: Our study reveals that HIF-1alpha increased ATG4B expression in NPC cells, and in turn upregulated the cisplatin (DDP)-induced protective autophagy, resulting in enhanced killing effect of DDP to NPC cells. Cisplatin 123-126 hypoxia inducible factor 1 subunit alpha Homo sapiens 32-42 32972441-0 2020 microRNA-216b enhances cisplatin-induced apoptosis in osteosarcoma MG63 and SaOS-2 cells by binding to JMJD2C and regulating the HIF1alpha/HES1 signaling axis. Cisplatin 23-32 hypoxia inducible factor 1 subunit alpha Homo sapiens 129-138 32522234-15 2020 CONCLUSIONS: Collectively, our current results strongly suggest that miR-424 tightly participates in the acquisition/maintenance of CDDP-resistant phenotype of bladder cancer cells through down-regulation of its targets UNC5B and SIRT4, and thus combination chemotherapy of CDDP plus HIF-1alpha/miR-424 inhibition might have a significant impact on hypoxic as well as normoxic bladder cancer cells. Cisplatin 132-136 hypoxia inducible factor 1 subunit alpha Homo sapiens 284-294 32328193-6 2020 Further, we showed that HMGB1 has an important role in mediating cisplatin resistance via an HMGB1/ nuclear factor kappa-B (NF-kappaB)/ hypoxia inducible factor-1alpha (HIF-1alpha) feedback loop. Cisplatin 65-74 hypoxia inducible factor 1 subunit alpha Homo sapiens 136-167 32328193-6 2020 Further, we showed that HMGB1 has an important role in mediating cisplatin resistance via an HMGB1/ nuclear factor kappa-B (NF-kappaB)/ hypoxia inducible factor-1alpha (HIF-1alpha) feedback loop. Cisplatin 65-74 hypoxia inducible factor 1 subunit alpha Homo sapiens 169-179 30464533-6 2018 GLUT-1 siRNA, LY294002 and cisplatin effectively inhibited the mRNA expressions and protein expressions of GLUT-1, Akt, PI3k and HIF-1alpha in Hep-2 cells. Cisplatin 27-36 hypoxia inducible factor 1 subunit alpha Homo sapiens 129-139 32194844-0 2020 One-pot synthesis of a microporous organosilica-coated cisplatin nanoplatform for HIF-1-targeted combination cancer therapy. Cisplatin 55-64 hypoxia inducible factor 1 subunit alpha Homo sapiens 82-87 32194844-3 2020 Methods: In this study, we developed a one-pot synthesis method for a microporous organosilica shell-coated cisplatin nanoplatform using a reverse microemulsion method, and explored its application in co-delivering acriflavine (ACF) for inhibiting hypoxia-inducible factor-1 (HIF-1). Cisplatin 108-117 hypoxia inducible factor 1 subunit alpha Homo sapiens 248-274 32194844-3 2020 Methods: In this study, we developed a one-pot synthesis method for a microporous organosilica shell-coated cisplatin nanoplatform using a reverse microemulsion method, and explored its application in co-delivering acriflavine (ACF) for inhibiting hypoxia-inducible factor-1 (HIF-1). Cisplatin 108-117 hypoxia inducible factor 1 subunit alpha Homo sapiens 276-281 32194844-6 2020 After reaching the tumor sites, cisplatin induced cancer cell death and activated HIF-1 pathways, resulting in acquired drug resistance and tumor metastasis. Cisplatin 32-41 hypoxia inducible factor 1 subunit alpha Homo sapiens 82-87 32194844-7 2020 To address this issue, ACF was co-loaded with cisplatin to prevent the formation of HIF-1alpha/beta dimers and suppress HIF-1 function. Cisplatin 46-55 hypoxia inducible factor 1 subunit alpha Homo sapiens 84-94 32194844-7 2020 To address this issue, ACF was co-loaded with cisplatin to prevent the formation of HIF-1alpha/beta dimers and suppress HIF-1 function. Cisplatin 46-55 hypoxia inducible factor 1 subunit alpha Homo sapiens 84-89 31700155-5 2020 pGSN, secreted and transported via exosomes (Ex-pGSN), upregulates HIF1alpha-mediated pGSN expression in chemoresistant OVCA cells in an autocrine manner as well as confers cisplatin resistance in otherwise chemosensitive OVCA cells. Cisplatin 173-182 hypoxia inducible factor 1 subunit alpha Homo sapiens 67-76 28442599-0 2019 Overcoming cisplatin resistance in osteosarcoma through the miR-199a-modulated inhibition of HIF-1alpha. Cisplatin 11-20 hypoxia inducible factor 1 subunit alpha Homo sapiens 93-103 28442599-7 2019 Intriguingly, cisplatin resistant osteosarcoma cells display significantly elevated HIF-1alpha expression under hypoxia. Cisplatin 14-23 hypoxia inducible factor 1 subunit alpha Homo sapiens 84-94 28442599-8 2019 We report here overexpression of miR-199a re-sensitizes cisplatin resistant cells to cisplatin through inhibition of HIF-1alpha in vitro and in vivo Finally, by analyzing the clinical osteosarcoma patient samples, we demonstrate a reverse correlation between miR-199a and HIF-1alpha mRNAs. Cisplatin 85-94 hypoxia inducible factor 1 subunit alpha Homo sapiens 117-127 31169018-2 2019 However, the correlation between HIF1alpha and the sensitivity of human non-small cell lung cancer (NSCLC) cells to cisplatin has not been illuminated. Cisplatin 116-125 hypoxia inducible factor 1 subunit alpha Homo sapiens 33-42 31169018-11 2019 This study revealed that hypoxia-improved cisplatin chemoresistance of NSCLC cells by regulated MDR1 and MRP1 expression via HIF1alpha/ROS pathway is reversed by LW6, suggesting that LW6 may act as effective sensitizer in chemotherapy for NSCLC. Cisplatin 42-51 hypoxia inducible factor 1 subunit alpha Homo sapiens 125-134 30867818-0 2019 Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1alpha-mediated regulation of apoptosis and autophagy. Cisplatin 51-60 hypoxia inducible factor 1 subunit alpha Homo sapiens 87-97 30867818-15 2019 Conclusion: HIF-1alpha and HDAC4 may mediate the interaction between p53 and RAS signaling to actively control ovarian cancer cisplatin resistance through dysregulation of apoptosis and autophagy. Cisplatin 126-135 hypoxia inducible factor 1 subunit alpha Homo sapiens 12-22 30464533-10 2018 Additionally, the synergistic effect between LY294002 and cisplatin to suppress the proliferation of Hep-2 might not be from GLUT-1, Akt, PI3k and HIF-1alpha; the synergistic effect between GLUT-1 siRNA and cisplatin to suppress the proliferation of Hep-2 might not be from GLUT-1, Akt and PI3k and might be more or less related to HIF-1alpha. Cisplatin 58-67 hypoxia inducible factor 1 subunit alpha Homo sapiens 332-342 32021271-11 2020 More importantly, HIF1a knock-down or miR-194-5p overexpression reversed PVT1-induced promotion of OSCC cell proliferation and cisplatin resistance. Cisplatin 127-136 hypoxia inducible factor 1 subunit alpha Homo sapiens 18-23 31088908-12 2019 TPT-mediated downregulation of HIF1alpha in hypoxic cells required TOPO1 resident on HIF1alpha mRNA, restored p53 transcriptional activity, downregulated ABCB1/ABCB5 cell surface expression, and reversed hypoxia-related cisplatin and paclitaxel resistance. Cisplatin 220-229 hypoxia inducible factor 1 subunit alpha Homo sapiens 31-40 30464533-7 2018 Furthermore, GLUT-1 siRNA and cisplatin demonstrated a synergism to inhibit the mRNA expression of HIF-1alpha. Cisplatin 30-39 hypoxia inducible factor 1 subunit alpha Homo sapiens 99-109 30347860-9 2018 The results indicated the potential benefit of combination therapy with HIF-1 and STAT3 inhibitors in overcoming HICR to free or micellar cisplatin. Cisplatin 138-147 hypoxia inducible factor 1 subunit alpha Homo sapiens 72-77 29971135-0 2018 Hypoxia exposure induced cisplatin resistance partially via activating p53 and hypoxia inducible factor-1alpha in non-small cell lung cancer A549 cells. Cisplatin 25-34 hypoxia inducible factor 1 subunit alpha Homo sapiens 79-110 30223937-0 2018 HIF-1alpha-induced autophagy contributes to cisplatin resistance in ovarian cancer cells. Cisplatin 44-53 hypoxia inducible factor 1 subunit alpha Homo sapiens 0-10 30223937-5 2018 Furthermore, GFP-tagged LC3 plasmid transfection and western blot were used to demonstrate that hypoxia induced chemoresistance of OVCAR-3 cells to cisplatin is related to HIF-1alpha-induced autophagy. Cisplatin 148-157 hypoxia inducible factor 1 subunit alpha Homo sapiens 172-182 30223937-6 2018 All these findings suggest that the cisplatin resistance of ovarian cancer cells is associated with HIF-1alpha-induced autophagy. Cisplatin 36-45 hypoxia inducible factor 1 subunit alpha Homo sapiens 100-110 29971135-4 2018 In the present study, the effects of hypoxia on the response of the NSCLC A549 cell line to the clinically relevant cytotoxic cisplatin were evaluated via regulating hypoxia inducible facor-1alpha (HIF-1alpha) and p53. Cisplatin 126-135 hypoxia inducible factor 1 subunit alpha Homo sapiens 198-208 29971135-6 2018 HIF-1alpha-knockdown also sensitized A549 cells to cisplatin in hypoxia-exposed, but not in normoxia-exposed A549 cells, suggesting that hypoxia-induced cisplatin resistance partially contributes toward the upregulation of HIF-1alpha by hypoxia exposure. Cisplatin 51-60 hypoxia inducible factor 1 subunit alpha Homo sapiens 0-10 29971135-6 2018 HIF-1alpha-knockdown also sensitized A549 cells to cisplatin in hypoxia-exposed, but not in normoxia-exposed A549 cells, suggesting that hypoxia-induced cisplatin resistance partially contributes toward the upregulation of HIF-1alpha by hypoxia exposure. Cisplatin 153-162 hypoxia inducible factor 1 subunit alpha Homo sapiens 0-10 29971135-6 2018 HIF-1alpha-knockdown also sensitized A549 cells to cisplatin in hypoxia-exposed, but not in normoxia-exposed A549 cells, suggesting that hypoxia-induced cisplatin resistance partially contributes toward the upregulation of HIF-1alpha by hypoxia exposure. Cisplatin 153-162 hypoxia inducible factor 1 subunit alpha Homo sapiens 223-233 29971135-9 2018 Taken together, these results identified the exact effects of HIF-1alpha and p53 induced by hypoxia and potentially elucidated their protective effects on A549 cells against cisplatin. Cisplatin 174-183 hypoxia inducible factor 1 subunit alpha Homo sapiens 62-72 29690507-0 2018 Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1alpha and Mutant p53 and Can Be Overcome by Induction of Oxidative Stress. Cisplatin 16-25 hypoxia inducible factor 1 subunit alpha Homo sapiens 88-98 29690507-3 2018 This study focusses on the role of hypoxia-inducible factor-1α (HIF-1α) and the p53 tumor suppressor protein in hypoxia-induced cisplatin resistance in non-small cell lung cancer (NSCLC) cells and the potential of APR-246 to overcome this resistance. Cisplatin 148-157 hypoxia inducible factor 1 subunit alpha Homo sapiens 74-79 29690507-5 2018 Cisplatin reduced HIF-1α protein levels in NCI-H2228Q331* cells, leading to a shift in expression from HIF-1α-dependent to p53-dependent transcription targets under hypoxia. Cisplatin 0-9 hypoxia inducible factor 1 subunit alpha Homo sapiens 18-33 29690507-5 2018 Cisplatin reduced HIF-1α protein levels in NCI-H2228Q331* cells, leading to a shift in expression from HIF-1α-dependent to p53-dependent transcription targets under hypoxia. Cisplatin 0-9 hypoxia inducible factor 1 subunit alpha Homo sapiens 18-23 28543796-4 2017 In this study, we demonstrated that HIF-1alpha-induced Mxd1 contributed to CDDP resistance in hypoxic U-2OS and MG-63 cells. Cisplatin 75-79 hypoxia inducible factor 1 subunit alpha Homo sapiens 36-46 29276393-0 2017 miR-199a modulates cisplatin resistance in ovarian cancer by targeting Hif1alpha. Cisplatin 19-28 hypoxia inducible factor 1 subunit alpha Homo sapiens 71-80 29212260-5 2017 Consistent with these data we observed increased reactive oxygen species (ROS) production and increased hypoxia inducible factor 1-alpha (HIF1alpha) stabilization in cisplatin resistant cells when compared to cisplatin sensitive controls. Cisplatin 166-175 hypoxia inducible factor 1 subunit alpha Homo sapiens 104-136 29212260-5 2017 Consistent with these data we observed increased reactive oxygen species (ROS) production and increased hypoxia inducible factor 1-alpha (HIF1alpha) stabilization in cisplatin resistant cells when compared to cisplatin sensitive controls. Cisplatin 166-175 hypoxia inducible factor 1 subunit alpha Homo sapiens 138-147 28878571-0 2017 Ribonucleic acid interference knockdown of IL-6 enhances the efficacy of cisplatin in laryngeal cancer stem cells by down-regulating the IL-6/STAT3/HIF1 pathway. Cisplatin 73-82 hypoxia inducible factor 1 subunit alpha Homo sapiens 148-152 28878571-15 2017 IL-6, STAT3 and HIF1 immunoreactive cell counts were further reduced in tissue where IL-6 knockdown was combined with cisplatin treatment as compared with tissue receiving cisplatin alone. Cisplatin 118-127 hypoxia inducible factor 1 subunit alpha Homo sapiens 16-20 27762347-0 2016 Metformin sensitizes the response of oral squamous cell carcinoma to cisplatin treatment through inhibition of NF-kappaB/HIF-1alpha signal axis. Cisplatin 69-78 hypoxia inducible factor 1 subunit alpha Homo sapiens 121-131 28790395-0 2017 Knockdown of HIF-1alpha by siRNA-expressing plasmid delivered by attenuated Salmonella enhances the antitumor effects of cisplatin on prostate cancer. Cisplatin 121-130 hypoxia inducible factor 1 subunit alpha Homo sapiens 13-23 28233769-0 2017 Erratum: Metformin sensitizes the response of oral squamous cell carcinoma to cisplatin treatment through inhibition of NF-kappaB/HIF-1alpha signal axis. Cisplatin 78-87 hypoxia inducible factor 1 subunit alpha Homo sapiens 130-140 27708247-6 2016 Addition of scriptaid also overcomes the cisplatin resistance exhibited in lung cancer cells with stabilized hypoxia inducible factor 1 (HIF1)-alpha (mutant) and mutant p53. Cisplatin 41-50 hypoxia inducible factor 1 subunit alpha Homo sapiens 109-148 27122375-8 2016 RESULTS: Both taxotere- and cisplatin-resistant MDAH-2774 and SKOV-3 EOC cell lines manifested a significant decrease in VEGF, VEGF receptors, HIF-1alpha messenger RNA, and protein levels as compared to their chemosensitive counterparts. Cisplatin 28-37 hypoxia inducible factor 1 subunit alpha Homo sapiens 143-153 27122375-10 2016 CONCLUSION: Cisplatin- and taxotere-resistant EOC cells are characterized by lower VEGF, VEGF receptors, and HIF-1alpha, and decreased angiogenesis. Cisplatin 12-21 hypoxia inducible factor 1 subunit alpha Homo sapiens 109-119 27765932-0 2016 Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1alpha, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation. Cisplatin 0-9 hypoxia inducible factor 1 subunit alpha Homo sapiens 130-140 27765932-5 2016 We report here that cisplatin supppresses ASS1 expression is due to upregulation of HIF-1alpha and downregulation of c-Myc, which function as negative and positive regulators of ASS1 expression, respectively, by reciprocal bindings to the ASS1 promoter. Cisplatin 20-29 hypoxia inducible factor 1 subunit alpha Homo sapiens 84-94 26717965-0 2016 HIF-1alpha/MDR1 pathway confers chemoresistance to cisplatin in bladder cancer. Cisplatin 51-60 hypoxia inducible factor 1 subunit alpha Homo sapiens 0-10 27473145-5 2016 However, combined treatment with GA and CDDP revealed a strong synergistic action between these drugs, and higher protein levels of the apoptosis-related factor Fas, cleaved caspase-8 and cleaved caspase-3 and lower expression of hypoxia-inducible factor (HIF)-1alpha are detected in both cell lines. Cisplatin 40-44 hypoxia inducible factor 1 subunit alpha Homo sapiens 230-267 27492148-7 2016 High levels of mTOR, HIF-1alpha, c-Myc, and PKM2 were associated with a positive chemotherapy response in cervical cancer patients treated with cisplatin-based NACT. Cisplatin 144-153 hypoxia inducible factor 1 subunit alpha Homo sapiens 21-31 27016414-0 2016 MicroRNA-421 regulated by HIF-1alpha promotes metastasis, inhibits apoptosis, and induces cisplatin resistance by targeting E-cadherin and caspase-3 in gastric cancer. Cisplatin 90-99 hypoxia inducible factor 1 subunit alpha Homo sapiens 26-36 26801746-0 2016 Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism. Cisplatin 11-20 hypoxia inducible factor 1 subunit alpha Homo sapiens 69-74 26801746-3 2016 By using two pairs of genetically matched cisplatin-sensitive and cisplatin-resistant ovarian cancer cell lines, we tested the hypothesis that downregulating hypoxia-inducible factor-1 (HIF-1), which regulates metabolic enzymes involved in glycolysis, is a promising strategy for overcoming cisplatin resistance of human ovarian cancer cells. Cisplatin 42-51 hypoxia inducible factor 1 subunit alpha Homo sapiens 158-184 26801746-3 2016 By using two pairs of genetically matched cisplatin-sensitive and cisplatin-resistant ovarian cancer cell lines, we tested the hypothesis that downregulating hypoxia-inducible factor-1 (HIF-1), which regulates metabolic enzymes involved in glycolysis, is a promising strategy for overcoming cisplatin resistance of human ovarian cancer cells. Cisplatin 42-51 hypoxia inducible factor 1 subunit alpha Homo sapiens 186-191 26801746-3 2016 By using two pairs of genetically matched cisplatin-sensitive and cisplatin-resistant ovarian cancer cell lines, we tested the hypothesis that downregulating hypoxia-inducible factor-1 (HIF-1), which regulates metabolic enzymes involved in glycolysis, is a promising strategy for overcoming cisplatin resistance of human ovarian cancer cells. Cisplatin 66-75 hypoxia inducible factor 1 subunit alpha Homo sapiens 158-184 26801746-3 2016 By using two pairs of genetically matched cisplatin-sensitive and cisplatin-resistant ovarian cancer cell lines, we tested the hypothesis that downregulating hypoxia-inducible factor-1 (HIF-1), which regulates metabolic enzymes involved in glycolysis, is a promising strategy for overcoming cisplatin resistance of human ovarian cancer cells. Cisplatin 66-75 hypoxia inducible factor 1 subunit alpha Homo sapiens 186-191 26801746-3 2016 By using two pairs of genetically matched cisplatin-sensitive and cisplatin-resistant ovarian cancer cell lines, we tested the hypothesis that downregulating hypoxia-inducible factor-1 (HIF-1), which regulates metabolic enzymes involved in glycolysis, is a promising strategy for overcoming cisplatin resistance of human ovarian cancer cells. Cisplatin 66-75 hypoxia inducible factor 1 subunit alpha Homo sapiens 158-184 26801746-3 2016 By using two pairs of genetically matched cisplatin-sensitive and cisplatin-resistant ovarian cancer cell lines, we tested the hypothesis that downregulating hypoxia-inducible factor-1 (HIF-1), which regulates metabolic enzymes involved in glycolysis, is a promising strategy for overcoming cisplatin resistance of human ovarian cancer cells. Cisplatin 66-75 hypoxia inducible factor 1 subunit alpha Homo sapiens 186-191 26801746-4 2016 We found that cisplatin downregulated the level of the regulatable alpha subunit of HIF-1, HIF-1alpha, in cisplatin-sensitive ovarian cancer cells through enhancing HIF-1alpha degradation but did not downregulate HIF-1alpha in their cisplatin-resistant counterparts. Cisplatin 14-23 hypoxia inducible factor 1 subunit alpha Homo sapiens 91-101 26801746-4 2016 We found that cisplatin downregulated the level of the regulatable alpha subunit of HIF-1, HIF-1alpha, in cisplatin-sensitive ovarian cancer cells through enhancing HIF-1alpha degradation but did not downregulate HIF-1alpha in their cisplatin-resistant counterparts. Cisplatin 14-23 hypoxia inducible factor 1 subunit alpha Homo sapiens 165-175 26801746-4 2016 We found that cisplatin downregulated the level of the regulatable alpha subunit of HIF-1, HIF-1alpha, in cisplatin-sensitive ovarian cancer cells through enhancing HIF-1alpha degradation but did not downregulate HIF-1alpha in their cisplatin-resistant counterparts. Cisplatin 106-115 hypoxia inducible factor 1 subunit alpha Homo sapiens 91-101 26801746-4 2016 We found that cisplatin downregulated the level of the regulatable alpha subunit of HIF-1, HIF-1alpha, in cisplatin-sensitive ovarian cancer cells through enhancing HIF-1alpha degradation but did not downregulate HIF-1alpha in their cisplatin-resistant counterparts. Cisplatin 106-115 hypoxia inducible factor 1 subunit alpha Homo sapiens 91-101 26801746-5 2016 Overexpression of a degradation-resistant HIF-1alpha (HIF-1alpha DeltaODD) reduced cisplatin-induced apoptosis in cisplatin-sensitive cells, whereas genetic knockdown of HIF-1alpha or pharmacological promotion of HIF-1alpha degradation enhanced response to cisplatin in both cisplatin-sensitive and cisplatin-resistant ovarian cancer cells. Cisplatin 83-92 hypoxia inducible factor 1 subunit alpha Homo sapiens 42-52 26801746-5 2016 Overexpression of a degradation-resistant HIF-1alpha (HIF-1alpha DeltaODD) reduced cisplatin-induced apoptosis in cisplatin-sensitive cells, whereas genetic knockdown of HIF-1alpha or pharmacological promotion of HIF-1alpha degradation enhanced response to cisplatin in both cisplatin-sensitive and cisplatin-resistant ovarian cancer cells. Cisplatin 83-92 hypoxia inducible factor 1 subunit alpha Homo sapiens 54-64 26801746-5 2016 Overexpression of a degradation-resistant HIF-1alpha (HIF-1alpha DeltaODD) reduced cisplatin-induced apoptosis in cisplatin-sensitive cells, whereas genetic knockdown of HIF-1alpha or pharmacological promotion of HIF-1alpha degradation enhanced response to cisplatin in both cisplatin-sensitive and cisplatin-resistant ovarian cancer cells. Cisplatin 83-92 hypoxia inducible factor 1 subunit alpha Homo sapiens 54-64 26801746-5 2016 Overexpression of a degradation-resistant HIF-1alpha (HIF-1alpha DeltaODD) reduced cisplatin-induced apoptosis in cisplatin-sensitive cells, whereas genetic knockdown of HIF-1alpha or pharmacological promotion of HIF-1alpha degradation enhanced response to cisplatin in both cisplatin-sensitive and cisplatin-resistant ovarian cancer cells. Cisplatin 83-92 hypoxia inducible factor 1 subunit alpha Homo sapiens 54-64 26801746-5 2016 Overexpression of a degradation-resistant HIF-1alpha (HIF-1alpha DeltaODD) reduced cisplatin-induced apoptosis in cisplatin-sensitive cells, whereas genetic knockdown of HIF-1alpha or pharmacological promotion of HIF-1alpha degradation enhanced response to cisplatin in both cisplatin-sensitive and cisplatin-resistant ovarian cancer cells. Cisplatin 114-123 hypoxia inducible factor 1 subunit alpha Homo sapiens 42-52 26801746-5 2016 Overexpression of a degradation-resistant HIF-1alpha (HIF-1alpha DeltaODD) reduced cisplatin-induced apoptosis in cisplatin-sensitive cells, whereas genetic knockdown of HIF-1alpha or pharmacological promotion of HIF-1alpha degradation enhanced response to cisplatin in both cisplatin-sensitive and cisplatin-resistant ovarian cancer cells. Cisplatin 114-123 hypoxia inducible factor 1 subunit alpha Homo sapiens 54-64 26801746-5 2016 Overexpression of a degradation-resistant HIF-1alpha (HIF-1alpha DeltaODD) reduced cisplatin-induced apoptosis in cisplatin-sensitive cells, whereas genetic knockdown of HIF-1alpha or pharmacological promotion of HIF-1alpha degradation enhanced response to cisplatin in both cisplatin-sensitive and cisplatin-resistant ovarian cancer cells. Cisplatin 114-123 hypoxia inducible factor 1 subunit alpha Homo sapiens 54-64 26801746-5 2016 Overexpression of a degradation-resistant HIF-1alpha (HIF-1alpha DeltaODD) reduced cisplatin-induced apoptosis in cisplatin-sensitive cells, whereas genetic knockdown of HIF-1alpha or pharmacological promotion of HIF-1alpha degradation enhanced response to cisplatin in both cisplatin-sensitive and cisplatin-resistant ovarian cancer cells. Cisplatin 114-123 hypoxia inducible factor 1 subunit alpha Homo sapiens 54-64 26801746-5 2016 Overexpression of a degradation-resistant HIF-1alpha (HIF-1alpha DeltaODD) reduced cisplatin-induced apoptosis in cisplatin-sensitive cells, whereas genetic knockdown of HIF-1alpha or pharmacological promotion of HIF-1alpha degradation enhanced response to cisplatin in both cisplatin-sensitive and cisplatin-resistant ovarian cancer cells. Cisplatin 114-123 hypoxia inducible factor 1 subunit alpha Homo sapiens 42-52 26801746-5 2016 Overexpression of a degradation-resistant HIF-1alpha (HIF-1alpha DeltaODD) reduced cisplatin-induced apoptosis in cisplatin-sensitive cells, whereas genetic knockdown of HIF-1alpha or pharmacological promotion of HIF-1alpha degradation enhanced response to cisplatin in both cisplatin-sensitive and cisplatin-resistant ovarian cancer cells. Cisplatin 114-123 hypoxia inducible factor 1 subunit alpha Homo sapiens 54-64 26801746-5 2016 Overexpression of a degradation-resistant HIF-1alpha (HIF-1alpha DeltaODD) reduced cisplatin-induced apoptosis in cisplatin-sensitive cells, whereas genetic knockdown of HIF-1alpha or pharmacological promotion of HIF-1alpha degradation enhanced response to cisplatin in both cisplatin-sensitive and cisplatin-resistant ovarian cancer cells. Cisplatin 114-123 hypoxia inducible factor 1 subunit alpha Homo sapiens 54-64 26801746-5 2016 Overexpression of a degradation-resistant HIF-1alpha (HIF-1alpha DeltaODD) reduced cisplatin-induced apoptosis in cisplatin-sensitive cells, whereas genetic knockdown of HIF-1alpha or pharmacological promotion of HIF-1alpha degradation enhanced response to cisplatin in both cisplatin-sensitive and cisplatin-resistant ovarian cancer cells. Cisplatin 114-123 hypoxia inducible factor 1 subunit alpha Homo sapiens 54-64 26801746-5 2016 Overexpression of a degradation-resistant HIF-1alpha (HIF-1alpha DeltaODD) reduced cisplatin-induced apoptosis in cisplatin-sensitive cells, whereas genetic knockdown of HIF-1alpha or pharmacological promotion of HIF-1alpha degradation enhanced response to cisplatin in both cisplatin-sensitive and cisplatin-resistant ovarian cancer cells. Cisplatin 114-123 hypoxia inducible factor 1 subunit alpha Homo sapiens 42-52 26801746-5 2016 Overexpression of a degradation-resistant HIF-1alpha (HIF-1alpha DeltaODD) reduced cisplatin-induced apoptosis in cisplatin-sensitive cells, whereas genetic knockdown of HIF-1alpha or pharmacological promotion of HIF-1alpha degradation enhanced response to cisplatin in both cisplatin-sensitive and cisplatin-resistant ovarian cancer cells. Cisplatin 114-123 hypoxia inducible factor 1 subunit alpha Homo sapiens 54-64 26801746-5 2016 Overexpression of a degradation-resistant HIF-1alpha (HIF-1alpha DeltaODD) reduced cisplatin-induced apoptosis in cisplatin-sensitive cells, whereas genetic knockdown of HIF-1alpha or pharmacological promotion of HIF-1alpha degradation enhanced response to cisplatin in both cisplatin-sensitive and cisplatin-resistant ovarian cancer cells. Cisplatin 114-123 hypoxia inducible factor 1 subunit alpha Homo sapiens 54-64 26801746-5 2016 Overexpression of a degradation-resistant HIF-1alpha (HIF-1alpha DeltaODD) reduced cisplatin-induced apoptosis in cisplatin-sensitive cells, whereas genetic knockdown of HIF-1alpha or pharmacological promotion of HIF-1alpha degradation enhanced response to cisplatin in both cisplatin-sensitive and cisplatin-resistant ovarian cancer cells. Cisplatin 114-123 hypoxia inducible factor 1 subunit alpha Homo sapiens 54-64 26801746-5 2016 Overexpression of a degradation-resistant HIF-1alpha (HIF-1alpha DeltaODD) reduced cisplatin-induced apoptosis in cisplatin-sensitive cells, whereas genetic knockdown of HIF-1alpha or pharmacological promotion of HIF-1alpha degradation enhanced response to cisplatin in both cisplatin-sensitive and cisplatin-resistant ovarian cancer cells. Cisplatin 114-123 hypoxia inducible factor 1 subunit alpha Homo sapiens 42-52 26801746-5 2016 Overexpression of a degradation-resistant HIF-1alpha (HIF-1alpha DeltaODD) reduced cisplatin-induced apoptosis in cisplatin-sensitive cells, whereas genetic knockdown of HIF-1alpha or pharmacological promotion of HIF-1alpha degradation enhanced response to cisplatin in both cisplatin-sensitive and cisplatin-resistant ovarian cancer cells. Cisplatin 114-123 hypoxia inducible factor 1 subunit alpha Homo sapiens 54-64 26801746-5 2016 Overexpression of a degradation-resistant HIF-1alpha (HIF-1alpha DeltaODD) reduced cisplatin-induced apoptosis in cisplatin-sensitive cells, whereas genetic knockdown of HIF-1alpha or pharmacological promotion of HIF-1alpha degradation enhanced response to cisplatin in both cisplatin-sensitive and cisplatin-resistant ovarian cancer cells. Cisplatin 114-123 hypoxia inducible factor 1 subunit alpha Homo sapiens 54-64 26801746-5 2016 Overexpression of a degradation-resistant HIF-1alpha (HIF-1alpha DeltaODD) reduced cisplatin-induced apoptosis in cisplatin-sensitive cells, whereas genetic knockdown of HIF-1alpha or pharmacological promotion of HIF-1alpha degradation enhanced response to cisplatin in both cisplatin-sensitive and cisplatin-resistant ovarian cancer cells. Cisplatin 114-123 hypoxia inducible factor 1 subunit alpha Homo sapiens 54-64 26801746-6 2016 We further demonstrated that knockdown of HIF-1alpha improved the response of cisplatin-resistant ovarian cancer cells to cisplatin by redirecting the aerobic glycolysis in the resistant cancer cells toward mitochondrial oxidative phosphorylation, leading to cell death through overproduction of reactive oxygen species. Cisplatin 78-87 hypoxia inducible factor 1 subunit alpha Homo sapiens 42-52 26801746-6 2016 We further demonstrated that knockdown of HIF-1alpha improved the response of cisplatin-resistant ovarian cancer cells to cisplatin by redirecting the aerobic glycolysis in the resistant cancer cells toward mitochondrial oxidative phosphorylation, leading to cell death through overproduction of reactive oxygen species. Cisplatin 122-131 hypoxia inducible factor 1 subunit alpha Homo sapiens 42-52 26801746-7 2016 Our findings suggest that the HIF-1alpha-regulated cancer metabolism pathway could be a novel target for overcoming cisplatin resistance in ovarian cancer. Cisplatin 116-125 hypoxia inducible factor 1 subunit alpha Homo sapiens 30-40 26548925-0 2015 SENP1 desensitizes hypoxic ovarian cancer cells to cisplatin by up-regulating HIF-1alpha. Cisplatin 51-60 hypoxia inducible factor 1 subunit alpha Homo sapiens 78-88 26548925-3 2015 In this study, we identified that SENP1 positively regulated the expression of HIF-1alpha by deSUMOylation and weakened the sensitivity of hypoxic ovarian cancer cells to cisplatin. Cisplatin 171-180 hypoxia inducible factor 1 subunit alpha Homo sapiens 79-89 26044673-0 2015 Enhanced renoprotective effect of HIF-1alpha modified human adipose-derived stem cells on cisplatin-induced acute kidney injury in vivo. Cisplatin 90-99 hypoxia inducible factor 1 subunit alpha Homo sapiens 34-44 26338199-6 2015 RT-PCR Array analysis showed that carbon ion beam combined with CDDP significantly induced apoptosis-related Cytochrome c, almost completely eliminated expression of the CSC markers CD44 and ESA, and significantly inhibited angiogenesis, and metastasis-related HIF1alpha and CD26 compared to carbon ion beam alone, X-ray alone, or X-ray combined with CDDP. Cisplatin 64-68 hypoxia inducible factor 1 subunit alpha Homo sapiens 261-270 26201611-3 2015 Our study demonstrated that hypoxia significantly protected A549 and SPC-A1 cells from cisplatin-induced cell death in a Hif-1alpha- and Hif-2alpha-dependent manner. Cisplatin 87-96 hypoxia inducible factor 1 subunit alpha Homo sapiens 121-131 26044673-4 2015 In this study, we investigated whether HIF-1alpha-modified adipose-derived stem cells (ASCs) had an enhanced protective effect on cisplatin-induced kidney injury in vivo. Cisplatin 130-139 hypoxia inducible factor 1 subunit alpha Homo sapiens 39-49 26044673-7 2015 In addition, we also found that HIF-1alpha-modified ASCs significantly increased HO-1 expression in cisplatin-induced AKI in vivo. Cisplatin 100-109 hypoxia inducible factor 1 subunit alpha Homo sapiens 32-42 26281060-9 2015 HIF-1alpha-RNAi-Hep-2 cells under hypoxia also showed certain resistance to apoptosis but the sensitivity to cisplatin was higher than that of Hep-2 cells. Cisplatin 109-118 hypoxia inducible factor 1 subunit alpha Homo sapiens 0-10 25608569-0 2015 Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1alpha destabilization. Cisplatin 37-46 hypoxia inducible factor 1 subunit alpha Homo sapiens 101-111 26281060-6 2015 After HIF-1alpha gene was silenced, the inhibition of cisplatin on Hep-2 cell proliferation was increased apparently, but was still interfered partly by hypoxia. Cisplatin 54-63 hypoxia inducible factor 1 subunit alpha Homo sapiens 6-16 25748238-0 2015 Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1alpha in EGFR-mutated lung cancer in vitro and in vivo. Cisplatin 10-19 hypoxia inducible factor 1 subunit alpha Homo sapiens 83-93 25748238-9 2015 These results suggest that low dose erlotinib-cisplatin combination exhibits its anti-tumor activity by targeting angiogenesis through the modulation of the c-MYC/HIF-1alpha/VEGF pathway in NSCLC with EGFR exon 19 deletions. Cisplatin 46-55 hypoxia inducible factor 1 subunit alpha Homo sapiens 163-173 24921917-8 2014 The upregulation of PAFR by CDDP correlated with the time-dependent accumulation of NF-kappaB and HIF-1alpha in the nucleus. Cisplatin 28-32 hypoxia inducible factor 1 subunit alpha Homo sapiens 98-108 24165223-0 2014 Up-regulation of survivin by AKT and hypoxia-inducible factor 1alpha contributes to cisplatin resistance in gastric cancer. Cisplatin 84-93 hypoxia inducible factor 1 subunit alpha Homo sapiens 37-68 24338158-0 2014 Human adipose-derived stem cells modified by HIF-1alpha accelerate the recovery of cisplatin-induced acute renal injury in vitro. Cisplatin 83-92 hypoxia inducible factor 1 subunit alpha Homo sapiens 45-55 24338158-5 2014 Cellular ultra-structure and TUNEL staining revealed that hASCs modified by HIF-1alpha promoted the recovery of apoptotic morphology in cisplatin-treated human kidney-2 cells (HK-2 cells) when compared to hASCs modified by empty-vector. Cisplatin 136-145 hypoxia inducible factor 1 subunit alpha Homo sapiens 76-86 24338158-6 2014 Additionally, hASCs modified by empty-vector inhibited caspase-3 expression and up-regulated Bcl-2 expression in cisplatin-treated HK-2 cells, an effect even more pronounced with hASCs modified by HIF-1alpha. Cisplatin 113-122 hypoxia inducible factor 1 subunit alpha Homo sapiens 197-207 24165223-5 2014 CDDP-resistant sub-lines generated from the parental SGC7901 and BGC823 cells by exposure to increasing concentrations of CDDP expressed higher levels of HIF-1alpha and survivin in response to hypoxia, and higher levels of phosphorylated AKT (pAKT). Cisplatin 0-4 hypoxia inducible factor 1 subunit alpha Homo sapiens 154-164 24165223-5 2014 CDDP-resistant sub-lines generated from the parental SGC7901 and BGC823 cells by exposure to increasing concentrations of CDDP expressed higher levels of HIF-1alpha and survivin in response to hypoxia, and higher levels of phosphorylated AKT (pAKT). Cisplatin 122-126 hypoxia inducible factor 1 subunit alpha Homo sapiens 154-164 24165223-8 2014 Specific inhibition of survivin, AKT and HIF-1alpha enhanced the sensitivity of CDDP-resistant cells to CDDP. Cisplatin 80-84 hypoxia inducible factor 1 subunit alpha Homo sapiens 41-51 24165223-8 2014 Specific inhibition of survivin, AKT and HIF-1alpha enhanced the sensitivity of CDDP-resistant cells to CDDP. Cisplatin 104-108 hypoxia inducible factor 1 subunit alpha Homo sapiens 41-51 24165223-10 2014 In summary, the results provide evidence that up-regulation of survivin by AKT and HIF-1alpha contributes to CDDP resistance, indicating that inhibition of these pathways may be a potential strategy for overcoming CDDP resistance in the treatment of gastric cancer. Cisplatin 109-113 hypoxia inducible factor 1 subunit alpha Homo sapiens 83-93 22467238-0 2012 HIF1alpha regulated expression of XPA contributes to cisplatin resistance in lung cancer. Cisplatin 53-62 hypoxia inducible factor 1 subunit alpha Homo sapiens 0-9 22432540-1 2012 This study aims to examine the contribution of PEG-conjugated hemoglobin combined with cisplatin to the expression of HIF-1alpha and MDR1 in a tumor xenograft model. Cisplatin 87-96 hypoxia inducible factor 1 subunit alpha Homo sapiens 118-128 21421285-0 2011 Noscapine sensitizes chemoresistant ovarian cancer cells to cisplatin through inhibition of HIF-1alpha. Cisplatin 60-69 hypoxia inducible factor 1 subunit alpha Homo sapiens 92-102 21964646-1 2012 This study aimed to investigate the effects of knocking down hypoxia-inducible factor-1alpha (HIF-1alpha) through RNA interference on hypoxia-induced increases in drug resistance in A549/CDDP cells, and to study the underlying mechanisms. Cisplatin 211-215 hypoxia inducible factor 1 subunit alpha Homo sapiens 61-104 21964646-1 2012 This study aimed to investigate the effects of knocking down hypoxia-inducible factor-1alpha (HIF-1alpha) through RNA interference on hypoxia-induced increases in drug resistance in A549/CDDP cells, and to study the underlying mechanisms. Cisplatin 211-215 hypoxia inducible factor 1 subunit alpha Homo sapiens 106-116 21964646-5 2012 Hypoxia increased the resistance of A549/CDDP cells to cisplatin and this effect was reversed by the siRNA inhibition of HIF-1alpha expression. Cisplatin 67-76 hypoxia inducible factor 1 subunit alpha Homo sapiens 133-143 21964646-7 2012 Hypoxia-induced resistance of A549/CDDP cells to cisplatin is reversed by the siRNA inhibition of HIF-1alpha expression. Cisplatin 61-70 hypoxia inducible factor 1 subunit alpha Homo sapiens 122-132 22336585-0 2012 Inhibition of the Rho/ROCK pathway enhances the efficacy of cisplatin through the blockage of hypoxia-inducible factor-1alpha in human ovarian cancer cells. Cisplatin 60-69 hypoxia inducible factor 1 subunit alpha Homo sapiens 94-125 22336585-6 2012 Furthermore, knockdown of HIF-1alpha using small interfering RNA enhanced cisplatin-induced growth inhibition and apoptosis as did inhibition of the Rho/ROCK pathway by fasudil, the Rho/ROCK inhibitor Y27632, or by Rho/ROCK knockdown. Cisplatin 74-83 hypoxia inducible factor 1 subunit alpha Homo sapiens 26-36 16532342-12 2006 Hypoxia-induced resistance to cisplatin and doxorubicin were reversed in SPCA1/HIF-1alpha(-) and A549/HIF-1alpha(-) cells. Cisplatin 30-39 hypoxia inducible factor 1 subunit alpha Homo sapiens 79-89 17470361-6 2007 We also found that: (1) luciferase activity mediated by the VEGF reporter containing a mutation of the HIF-1 binding site was much lower than that of the reporter containing a wild-type HIF-1 binding site in ovarian cancer cells, thus confirming that HIF-1 is a major transcriptional regulator of VEGF expression; and that (2) CDDP greatly inhibited VEGF reporter activity containing the wild-type but not the mutant HIF-1 binding site. Cisplatin 327-331 hypoxia inducible factor 1 subunit alpha Homo sapiens 103-108 17470361-7 2007 This result indicates that CDDP-inhibited VEGF transcriptional activation specifically by decreasing HIF-1 activity. Cisplatin 27-31 hypoxia inducible factor 1 subunit alpha Homo sapiens 101-106 17470361-9 2007 CDDP-inhibited VEGF transcriptional activation specifically through the expression of HIF-1alpha, but not HIF-1beta. Cisplatin 0-4 hypoxia inducible factor 1 subunit alpha Homo sapiens 86-96 17470361-11 2007 These results suggest a novel mechanism of CDDP"s anti-tumor activity in ovarian cancer cells via HIF-1 expression and VEGF transcriptional activation. Cisplatin 43-47 hypoxia inducible factor 1 subunit alpha Homo sapiens 98-103 16532342-0 2006 Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Cisplatin 30-39 hypoxia inducible factor 1 subunit alpha Homo sapiens 115-125 19447872-7 2009 Akt/HIF-1alpha/PDGF-BB signaling regulated Akt to confer cisplatin resistance to HCC cell lines in vitro. Cisplatin 57-66 hypoxia inducible factor 1 subunit alpha Homo sapiens 4-14 18421307-0 2008 Effects of lentivirus-mediated HIF-1alpha knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells. Cisplatin 71-80 hypoxia inducible factor 1 subunit alpha Homo sapiens 31-41 18421307-9 2008 HIF-1alpha knockdown could reverse hypoxia-related resistance to cisplatin and apoptotic resistance only in HT1080 cells, but had little effect on HT1080-6TG cells. Cisplatin 65-74 hypoxia inducible factor 1 subunit alpha Homo sapiens 0-10 18421307-11 2008 In summary, HIF-1 targeted therapy to reverse hypoxia-related cisplatin resistance depends on normal p53 status. Cisplatin 62-71 hypoxia inducible factor 1 subunit alpha Homo sapiens 12-17 17498666-2 2007 We have examined whether the DNA-damaging drugs cisplatin and doxorubicin and the microtubule inhibitors docetaxel and paclitaxel can affect VEGF expression and HIF-1 activity in three human ovarian cancer cell lines. Cisplatin 48-57 hypoxia inducible factor 1 subunit alpha Homo sapiens 161-166 17498666-4 2007 Transient transfection with a HIF-1-responsive luciferase construct indicated that cisplatin and doxorubicin inhibited hypoxic activation of HIF-1. Cisplatin 83-92 hypoxia inducible factor 1 subunit alpha Homo sapiens 30-35 17498666-4 2007 Transient transfection with a HIF-1-responsive luciferase construct indicated that cisplatin and doxorubicin inhibited hypoxic activation of HIF-1. Cisplatin 83-92 hypoxia inducible factor 1 subunit alpha Homo sapiens 141-146 17498666-5 2007 Cisplatin repressed HIF-1alpha protein expression in all cell lines. Cisplatin 0-9 hypoxia inducible factor 1 subunit alpha Homo sapiens 20-30 17498666-6 2007 Stimulation of HIF-1alpha protein degradation by cisplatin was observed in the only cell line expressing wild-type p53. Cisplatin 49-58 hypoxia inducible factor 1 subunit alpha Homo sapiens 15-25 17498666-7 2007 Cisplatin also inhibited the synthesis of HIF-1alpha protein for which p53 was dispensable. Cisplatin 0-9 hypoxia inducible factor 1 subunit alpha Homo sapiens 42-52 17498666-8 2007 Interestingly, cisplatin strongly reduced the protein levels of the HIF-1 coactivators p300 and CREB-binding protein (CBP) under hypoxia in all cell lines. Cisplatin 15-24 hypoxia inducible factor 1 subunit alpha Homo sapiens 68-73 17498666-11 2007 In total, our findings indicate that cisplatin and doxorubicin can repress hypoxic induction of VEGF expression by inhibiting HIF-1 through different mechanisms. Cisplatin 37-46 hypoxia inducible factor 1 subunit alpha Homo sapiens 126-131 17066447-4 2007 In this study, we investigated the influence of HIF-1alpha expression on the susceptibility of oral squamous cell carcinoma (OSCC) cells to chemotherapeutic drugs (cis-diamminedichloroplatinum and 5-fluorouracil) and gamma-rays. Cisplatin 164-192 hypoxia inducible factor 1 subunit alpha Homo sapiens 48-58 15130309-2 2004 METHODS: Culturing human lung adenocarcinoma A549 cell in hypoxia (2%O2) for 24 h, the expression of hypoxia inducible factor-1alpha, P-gp and multidrug resistance protein was detected by using immunohistochemistry, and after action of adriamycin or cisplatin in hypoxia (2%O2) for 24, the cell survival rate was detected by MTT. Cisplatin 250-259 hypoxia inducible factor 1 subunit alpha Homo sapiens 101-132